This blog post deals about the oxidative stress discovered by OXIS International, Inc. is engaged in the research, development and sale of products that counteract the harmful effects of “oxidative stress.”
Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised. products include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised. products include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
In February 2006, it moved key administrative functions to its U.S. FDA certified cGMP device manufacturing facility in Foster City, CA This blog post deals about the oxidative stress discovered by OXIS International, Inc. is engaged in the research, development and sale of products that counteract the harmful effects of “oxidative stress.” Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised. Products include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
